rilpivirine (edurant) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is active against wild-type and NNRTI-resistant HIV-1. Rilpivirine is a diarylpyrimidinethat inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$6.6676

United States

$27.1280 - $39.2748
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( cabotegravir (Vocabria), rilpivirine (edurant) - other name: cabotegravir and rilpivirine -extended release injectable suspension )
|
( tenofovir (viread), emtricitabine (emtriva), rilpivirine (edurant) )
|
( dolutegravir (tivicay), rilpivirine (edurant) )
|
( emtricitabine (emtriva), tenofovir alafenamide (genvoya), rilpivirine (edurant) )

Alternative names

4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile | edurant | emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide | emtricitabine / rilpivirine hydrochloride /tenofovir disoproxil fumarate | r-278474 | rilipivirine | rilpivirine | rilpivirine hcl | rilpivirine hydrochloride | rllpivirine | tmc278 | tmc-278 | tmc278-hydrochloride | tmc278la

Organizations (70)

Research & Development (66)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (2)


 

HIV-1 (approved 2011)

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Antiretroviral Therapy, Highly Active (Phase 4)

Biological Availability (Phase 1)

Cardiovascular Diseases (Phase 4)

Cognition Disorders (Phase 4)

Contraception (Phase 2)

Contraceptives, Oral (Phase 1)

Depression (Phase 4)

Drugs, Investigational (Phase 2/Phase 3)

Fatty Liver (Phase 4)

Healthy Volunteers (Phase 4)

Hepacivirus (Phase 1)

Hepatitis C (Phase 3)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV Infections (Phase 4)

Infections (Phase 2/Phase 3)

Kidney Failure, Chronic (Phase 4)

Liver Diseases (Phase 1)

Opioid-Related Disorders (Early Phase 1)

Patient Compliance (Phase 4)

Pharmacokinetics (Phase 1)

Pregnancy (Phase 3)

Quality of Life (Phase 4)

Sleep Disorders, Intrinsic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 108
  • # of Trial Organizations: 66

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue